The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical. The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use […]
Fresenius wins FDA breakthrough device nod for fluid management software
Fresenius (NYSE:FMS) said yesterday that it won FDA breakthrough device designation for its computer-assisted ultrafiltration control software intended to improve fluid management during hemodialysis. The Waltham, Mass.-based company said that the software is designed to work with its newer hemodialysis machines using its CLiC device. Fresenius said that with the software, it hopes to create a […]
FTC gives the go ahead to Fresenius, NxStage merger
The U.S. Federal Trade Commission said yesterday that it cleared Fresenius (NYSE:FMS) in its $2 billion acquisition of NxStage Medical (NSDQ:NXTM). As part of the approval, NxStage will have to part ways with its bloodline tubing set business, offloading them to B. Braun, according to the regulatory agency. The vote to approve the merger was split, however, […]
Fresenius launches 2008T BlueStar hemodialysis machine in U.S.
Fresenius Medical Care (NYSE:FMS) said today that it launched its 2008T BlueStar hemodialysis machine, touting more than 30 improvements from previous device models. The Waltham, Mass.-based company said that the new system is intended to allow for simpler operation and maintenance with additional treatment options, and added that the system features a number of newly automated technologies. […]
Laminate Medical brings in $12m for dialysis vascular support device
Israeli medtech start-up Laminate Medical Technologies said today that it raised $12 million in a new round of financing slated to support its VasQ vascular support device. The company’s VasQ device is designed to aid kidney failure patients in need of dialysis by providing external support to reduce fistula failure. The VasQ regulates flow by […]
U.S. gov’t shutdown again delays closing for Fresenius-NxStage merger
Fresenius (NYSE:FMS) said today that an interruption to the FTC’s review of its merger with NxStage Medical (NSDQ:NXTM), caused by the partial U.S. government shutdown, has again delayed the end-date of the deal which has now been extended to August 6, 2019. The end-date is not hard-set, Fresenius said, and could occur on an earlier date if there have […]
Baxter launches on-demand peritoneal dialysis solution device trial
Baxter (NYSE:BAX) said yesterday that it launched an FDA-cleared clinical trial of its on-demand peritoneal dialysis solution generation system intended to allow patients to make peritoneal dialysis solutions in small batches at home. The system is designed to use a small water filtration device, concentrates and Deerfield, Ill.-based Baxter’s Amia automated peritoneal dialysis system to turn a […]
Fresenius still awaiting FTC approval for NxStage acquisition
Fresenius (NYSE:FMS) said last Friday that it is still in the process of seeking approval from the U.S. Federal Trade Commission for its $2 billion merger with NxStage Medical (NSDQ:NXTM). The tie-up, which was delayed by NxStage in October in light of the FTC investigation, has been in the works for nearly a year and a half, having […]
Fresenius slides on softened outlook
Fresenius (NYSE:FMS) shares are down roughly 10% today after the German dialysis giant softened its outlook. “Given its current expectations for 2018 and 2019, Fresenius now believes its ambitious group targets for 2020 will not be met,” Fresenius said. Overall earnings next year are now expected to be flat on mid-single-digit sales growth, compared with prior […]
NxStage Medical, Fresenius again delay $2B merger
NxStage Medical (NSDQ:NXTM) yesterday once more delayed its pending $2 billion merger with Fresenius (NYSE:FMS) as the U.S. Federal Trade Commission continues to examine the deal. In July, the German renal care giant and Lawrence, Mass.-based NxStage extended the deal’s closing date by 90 days, from August 7 to Nov. 5, saying it still expected to close the deal this year. […]
Fresenius plunges on missed prelims, guidance cut
Fresenius (NYSE:FMS) shares closed down some 17% yesterday after it cut its outlook for the rest of the year on lower-than-expected third-quarter results. The German dialysis giant released preliminary figures for the three months ended Sept. 30, saying it expects to report profits of €285 million on sales of €4.06 billion. Analysts were looking for sales of €4.12 billion. […]
- 1
- 2
- 3
- …
- 10
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube